BWX Technologies, Inc. (NYSE:BWXT) to Issue Quarterly Dividend of $0.27

BWX Technologies, Inc. (NYSE:BWXT) declared a quarterly dividend on Friday, July 31st. Investors of record on Tuesday, August 18th will be paid a dividend of 0.27 per share by the technology company on Friday, September 4th. This represents a c) dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend is Tuesday, August 18th.

BWX Technologies has increased its dividend by an average of 0.1%per year over the last three years and has raised its dividend annually for the last 2 consecutive years. BWX Technologies has a dividend payout ratio of 27.6% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect BWX Technologies to earn $5.25 per share next year, which means the company should continue to be able to cover its $1.08 annual dividend with an expected future payout ratio of 20.6%.

BWX Technologies Price Performance

BWXT stock opened at $173.14 on Friday. The stock has a 50-day moving average price of $183.41 and a two-hundred day moving average price of $199.07. BWX Technologies has a 12-month low of $157.10 and a 12-month high of $241.82. The company has a current ratio of 2.40, a quick ratio of 2.33 and a debt-to-equity ratio of 1.51. The company has a market cap of $15.86 billion, a PE ratio of 44.86, a price-to-earnings-growth ratio of 2.71 and a beta of 0.76.

BWX Technologies (NYSE:BWXT) last announced its quarterly earnings results on Monday, August 3rd. The technology company reported $1.07 EPS for the quarter, topping the consensus estimate of $1.04 by $0.03. The company had revenue of $901.62 million during the quarter, compared to analyst estimates of $902.41 million. BWX Technologies had a return on equity of 30.83% and a net margin of 10.11%.The firm’s revenue was up 18.0% on a year-over-year basis. During the same period in the prior year, the firm posted $1.02 earnings per share. BWX Technologies has set its FY 2026 guidance at 4.700-4.800 EPS. As a group, research analysts predict that BWX Technologies will post 4.75 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on BWXT shares. JPMorgan Chase & Co. started coverage on shares of BWX Technologies in a research report on Monday, July 27th. They set an “overweight” rating and a $230.00 target price for the company. Wall Street Zen cut shares of BWX Technologies from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. BTIG Research reissued a “buy” rating and issued a $235.00 price objective on shares of BWX Technologies in a research report on Tuesday, August 4th. Deutsche Bank Aktiengesellschaft raised shares of BWX Technologies from a “hold” rating to a “buy” rating and raised their target price for the company from $205.00 to $255.00 in a research note on Friday, May 15th. Finally, Weiss Ratings upgraded shares of BWX Technologies from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, BWX Technologies presently has a consensus rating of “Moderate Buy” and an average price target of $227.20.

About BWX Technologies

BWX Technologies, Inc (NYSE: BWXT) is a specialized supplier of nuclear components and services, primarily serving the U.S. government and commercial markets. The company’s core expertise lies in the design, fabrication and servicing of nuclear propulsion systems for the U.S. Navy, where it supports the maintenance and overhaul of naval nuclear reactors. In addition to defense applications, BWXT develops small modular reactors (SMRs), nuclear fuel and related technologies for non‐defense power generation, offering scalable solutions to meet evolving energy and industrial demands.

Beyond propulsion and power systems, BWXT is a leading producer of medical radioisotopes used in diagnostic imaging and cancer treatment.